Page 11234..1020..»

Category Archives: Ulcerative Colitis

New guidelines issued for patients with moderate-to-severe ulcerative colitis – Hospital Healthcare Europe

Posted: July 1, 2020 at 10:51 pm

The guideline sought to address the medical management of adult outpatients as well as those who are hospitalised with the condition. There are 11 recommendations and for each one there is an estimate of the strength of the recommendation (that is, strong, conditional or no recommendation) and the quality of the associated evidence (for example, high/moderate/low/very low/or evidence gap). Interestingly, only one recommendation was deemed as strong and based on moderate quality evidence Continue reading

Posted in Ulcerative Colitis | Comments Off on New guidelines issued for patients with moderate-to-severe ulcerative colitis – Hospital Healthcare Europe

Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study – GlobeNewswire

Posted: at 10:51 pm

June 25, 2020 08:00 ET | Source: Diversigen, Inc. ST. PAUL, Minn., June 25, 2020 (GLOBE NEWSWIRE) -- Diversigen, Inc., a subsidiary of OraSure Technologies Inc Continue reading

Posted in Ulcerative Colitis | Comments Off on Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study – GlobeNewswire

IBD: Will Zeposia change the treatment paradigm? – Pharmaceutical Technology

Posted: at 10:51 pm

Although there is genuine excitement surrounding Zeposia in the IBD community, there are several unknowns that still need to be resolved. Credit: Shutterstock + Emily frost Currently, in inflammatory bowel disease (IBD) there is an unmet need for novel oral drug formulations for patients with moderate-to-severe ulcerative colitis (UC) or Crohns disease (CD). Key opinion leaders (KOLs) interviewed by GlobalData in Q2 2020 believe that patients would prefer an oral formulation over the existing subcutaneously or intravenously delivered agents, as there is less concern surrounding immunogenicity and the route of administration is easier. Continue reading

Posted in Ulcerative Colitis | Comments Off on IBD: Will Zeposia change the treatment paradigm? – Pharmaceutical Technology

Ulcerative Colitis Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 – Cole of Duty

Posted: at 10:51 pm

Eli Lilly and Co The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. Continue reading

Posted in Ulcerative Colitis | Comments Off on Ulcerative Colitis Market Size, Analysis, Trends and Segmented Data by Top Companies and Opportunities 2020-2027 – Cole of Duty

Ulcerative Colitis Market: Rising Trends, Analysis With Top Key Players 2026 | Allergan, AbbVie Inc., Takeda Pharmaceutical Company Limited, Bayer AG,…

Posted: at 10:51 pm

This Ulcerative Colitis Market report is prepared with the detailed market analysis performed by a team of industry experts, skilful analysts, dynamic forecasters and knowledgeable researchers. Continue reading

Posted in Ulcerative Colitis | Comments Off on Ulcerative Colitis Market: Rising Trends, Analysis With Top Key Players 2026 | Allergan, AbbVie Inc., Takeda Pharmaceutical Company Limited, Bayer AG,…

Taiwan Study Ties IBD to Dementia – MedPage Today

Posted: at 10:51 pm

Inflammatory bowel disease (IBD) was associated with more than double the risk of dementia, particularly Alzheimer disease, a Taiwan population study found. Furthermore, individuals with IBD were diagnosed with dementia an average of 7 years earlier than non-IBD controls Continue reading

Posted in Ulcerative Colitis | Comments Off on Taiwan Study Ties IBD to Dementia – MedPage Today

Pfizer links with SidekickHealth for digital health solution – PharmaTimes

Posted: at 10:51 pm

Pfizer has linked with Nordic group SidekickHealth to launch a digital therapeutics platform designed to empower patients to take more control of their own health and boost wellbeing across Europe. According to the groups, scientific expertise and digital technologies have been combined to give patients a new tool to help them maintain healthy lifestyles and improve disease management and quality of life, while providing guidance and resources to facilitate communication with healthcare professionals. The platform focuses on a number of therapeutic areas Continue reading

Posted in Ulcerative Colitis | Comments Off on Pfizer links with SidekickHealth for digital health solution – PharmaTimes

How Coronavirus Pandemic Will Impact Inflammatory Bowel Disease Market 2020: Industry Size, Outlook, Share, Demand, Manufacturers and 2026 Forecast…

Posted: at 10:51 pm

Inflammatory Bowel Disease Market report provide the COVID19 Outbreak Impact analysis of key factors influencing the growth of the market Size (Production, Value and Consumption). This Inflammatory Bowel Disease industry splits the breakdown (data status 2014-2020 and Six years forecast 2020-2026), by manufacturers, region, type and application. This study also analyses the Inflammatory Bowel Disease market Status, Market Share, Growth Rate, Future Trends, Market Drivers, Opportunities and Challenges, Risks and Entry Barriers, Sales Channels, Distributors and Porters Five Forces Analysis. Continue reading

Posted in Ulcerative Colitis | Comments Off on How Coronavirus Pandemic Will Impact Inflammatory Bowel Disease Market 2020: Industry Size, Outlook, Share, Demand, Manufacturers and 2026 Forecast…

AltruBio Inc. moves forward with clinical development of Neihulizumab in Steroid-Refractory Acute Graft-versus-Host Disease after encouraging Phase 1a…

Posted: at 10:51 pm

The high response rate of Neihulizumab in this study encourages us to move this drug candidate forward. SR-aGVHD continues to be a significant unmet medical need and further treatment options are required. Continue reading

Posted in Ulcerative Colitis | Comments Off on AltruBio Inc. moves forward with clinical development of Neihulizumab in Steroid-Refractory Acute Graft-versus-Host Disease after encouraging Phase 1a…

Research Report 2020: Global Infliximab and biosimilar Market Company Overview, Growth And Forecast By 2025 – NJ MMA News

Posted: at 10:51 pm

Infliximab and biosimilar Market Summary 2020-2025 Garner Insights released a new market study on Infliximab and biosimilar Market 2020 with industry data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand Detailed analysis. At present, the market is developing its presence. The Research report presents a complete assessment of the Market and contains a future trend, current growth factors, attentive opinions, facts, and industry validated market data. Continue reading

Posted in Ulcerative Colitis | Comments Off on Research Report 2020: Global Infliximab and biosimilar Market Company Overview, Growth And Forecast By 2025 – NJ MMA News

Page 11234..1020..»